The ATLAS,AttOM, MA.17Rtrials evaluatedthis durationbenefit ofendocrine therapyBased onTAILORx, <50years receivechemoendocrinetherapy if theyhave thisOncotypeDx score This agent iswell studied fortamoxifeninduced hotflashes inbreast cancerI can give thisagent in highrisk BRCA1/2 mutationfor 1 yearThis agentshould beinitiated withneratinib for thefirst 8 weeksThis agent canbe added toLN+ HER2+disease givenwithtrastuzumabDuration of timepatients willtakeabemaciclib inearly stagediseaseThis treatmentmodality isalwayscombined withlumpectomysurgeryUsed asneoadjuvant andadjuvant therapyin high risk TNBCbased on theKEYNOTE 522trialThis drugclass are thebackbone ofHR+ diseaseThis agent cancauseendometrialcancer, but hasbone densityprotective effectBased onOncotype DX,a score of 35will receivethis treatmentThis should bemonitoredroutinely every3-4 monthswhile receivingtrastuzumab Patients withHER2+ diseasecontinuetargetedtherapy for thisdurationThis agent is notused inpremenopausalwomen as endocrinetherapy unless theyalso receive ovariansuppression The onlysteroidalaromataseinhibitor in itsdrug classThis prodrug isgiven in TNBC forpatients who do notachieve pathologiccomplete responsebased on CREATE-X trialThis drug class iscontraindicatedcombined withtrastuzumab-avoid for 7 monthsafter lasttrastuzumab dose1%Patients who donot achieve pCRin HER2+disease and haveresidual diseaseget this therapyPreferredregimen forHR+ diseasefor frail/elderlypatientsThis CDK 4/6inhibitor is the onlyone in its drugclass also used inearly stage breastcancerThis subtype ofbreast cancerhas the lowestrelative 5-yearsurvival rate Preferredfrequencyof GnRHagonistsThe ATLAS,AttOM, MA.17Rtrials evaluatedthis durationbenefit ofendocrine therapyBased onTAILORx, <50years receivechemoendocrinetherapy if theyhave thisOncotypeDx score This agent iswell studied fortamoxifeninduced hotflashes inbreast cancerI can give thisagent in highrisk BRCA1/2 mutationfor 1 yearThis agentshould beinitiated withneratinib for thefirst 8 weeksThis agent canbe added toLN+ HER2+disease givenwithtrastuzumabDuration of timepatients willtakeabemaciclib inearly stagediseaseThis treatmentmodality isalwayscombined withlumpectomysurgeryUsed asneoadjuvant andadjuvant therapyin high risk TNBCbased on theKEYNOTE 522trialThis drugclass are thebackbone ofHR+ diseaseThis agent cancauseendometrialcancer, but hasbone densityprotective effectBased onOncotype DX,a score of 35will receivethis treatmentThis should bemonitoredroutinely every3-4 monthswhile receivingtrastuzumab Patients withHER2+ diseasecontinuetargetedtherapy for thisdurationThis agent is notused inpremenopausalwomen as endocrinetherapy unless theyalso receive ovariansuppression The onlysteroidalaromataseinhibitor in itsdrug classThis prodrug isgiven in TNBC forpatients who do notachieve pathologiccomplete responsebased on CREATE-X trialThis drug class iscontraindicatedcombined withtrastuzumab-avoid for 7 monthsafter lasttrastuzumab dose1%Patients who donot achieve pCRin HER2+disease and haveresidual diseaseget this therapyPreferredregimen forHR+ diseasefor frail/elderlypatientsThis CDK 4/6inhibitor is the onlyone in its drugclass also used inearly stage breastcancerThis subtype ofbreast cancerhas the lowestrelative 5-yearsurvival rate Preferredfrequencyof GnRHagonists

BC questions - Call List

(Print) Use this randomly generated list as your call list when playing the game. There is no need to say the BINGO column name. Place some kind of mark (like an X, a checkmark, a dot, tally mark, etc) on each cell as you announce it, to keep track. You can also cut out each item, place them in a bag and pull words from the bag.


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
  1. The ATLAS, AttOM, MA.17R trials evaluated this duration benefit of endocrine therapy
  2. Based on TAILORx, <50 years receive chemoendocrine therapy if they have this OncotypeDx score
  3. This agent is well studied for tamoxifen induced hot flashes in breast cancer
  4. I can give this agent in high risk BRCA 1/2 mutation for 1 year
  5. This agent should be initiated with neratinib for the first 8 weeks
  6. This agent can be added to LN+ HER2+ disease given with trastuzumab
  7. Duration of time patients will take abemaciclib in early stage disease
  8. This treatment modality is always combined with lumpectomy surgery
  9. Used as neoadjuvant and adjuvant therapy in high risk TNBC based on the KEYNOTE 522 trial
  10. This drug class are the backbone of HR+ disease
  11. This agent can cause endometrial cancer, but has bone density protective effect
  12. Based on Oncotype DX, a score of 35 will receive this treatment
  13. This should be monitored routinely every 3-4 months while receiving trastuzumab
  14. Patients with HER2+ disease continue targeted therapy for this duration
  15. This agent is not used in premenopausal women as endocrine therapy unless they also receive ovarian suppression
  16. The only steroidal aromatase inhibitor in its drug class
  17. This prodrug is given in TNBC for patients who do not achieve pathologic complete response based on CREATE-X trial
  18. This drug class is contraindicated combined with trastuzumab- avoid for 7 months after last trastuzumab dose
  19. 1%
  20. Patients who do not achieve pCR in HER2+ disease and have residual disease get this therapy
  21. Preferred regimen for HR+ disease for frail/elderly patients
  22. This CDK 4/6 inhibitor is the only one in its drug class also used in early stage breast cancer
  23. This subtype of breast cancer has the lowest relative 5-year survival rate
  24. Preferred frequency of GnRH agonists